Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study.

ABSTRACT: OBJECTIVE:The objective of this study is to compare the risk of incident diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. METHODS:A new-user observational cohort study was conducted using data from a US commercial (Truven MarketScan, 2005-2016) claims database and a public insurance (Medicare, 2010-2014) claims database. Patients with RA who did not have DM were selected into one of eight exposure groups (abatacept, infliximab, adalimumab, golimumab, certolizumab, etanercept, tocilizumab, or tofacitinib) and observed for the outcome of incident DM, defined as a combination of a diagnosis code and initiation of a hypoglycemic treatment. A stabilized inverse probability-weighted Cox proportion

SUBMITTER: Desai RJ 

PROVIDER: S-EPMC7164631 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature